Chemotherapy and tamoxifen for breast cancer at 15 years*
| Treatment | Patient group | Annual rate ratio for breast cancer mortality over 15 y | Absolute improvement in breast cancer mortality | p Value | ||
|---|---|---|---|---|---|---|
| 5 y | 10 y | 15 y | ||||
| *ER = oestrogen receptor. | ||||||
| Polychemotherapy for 4–6 months including an anthracycline | Women <50 y | 0.62 | 4.7% | 7.9% | 10% | <0.001 |
| Women 50–60 y | 0.80 | 2.6% | 2.9% | 3.0% | <0.001 | |
| Tamoxifen for 5 y | Women with ER positive disease (any age) | 0.69 | 3.6% | 7.9% | 9.2% | <0.001 |